Roche/DeCode Genetics $200 mil. genomics deal to use Icelandic population data.
ROCHE/DECODE GENOMICS DEAL TO FOCUS ON SCHIZOPHRENIA, DIABETES and 10 other diseases under an agreement announced by the companies Feb. 2. The five-year deal, which is valued at over $200 mil., is being heralded by the firms as "the largest human genomics deal ever." The initial focus of the collaboration is understood to be on a group of six diseases including adult onset diabetes and schizophrenia, with another group of six being researched at a secondary level. The agreement will cover four cardiovascular diseases, four psychiatric/neurologic disorders and four metabolic diseases.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth